Computational Design of Fusion Inhibitors Targeting Drug-resistant HIVgp41
针对耐药 HIVgp41 的融合抑制剂的计算设计
基本信息
- 批准号:7495418
- 负责人:
- 金额:$ 27.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-04-01 至 2013-03-31
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAffectAffinityAntiviral AgentsApplied ResearchBindingBiologicalBiological AssayCell membraneClinicalClinical TrialsCollaborationsComplexComputer SimulationComputersComputing MethodologiesDataDevelopmentDiseaseDockingDropsDrug resistanceEnvironmentEquipmentEscape MutantEventFree EnergyFuzeonGlycoproteinsGoalsGrantHIVInfectionIntegrase InhibitorsKnowledgeLeadLettersLigand BindingLigandsLipid BilayersMediatingMembraneMembrane FusionMethodologyMolecularMolecular WeightMutateMutationPatientsPeptidesPersonsPharmaceutical PreparationsPoint MutationProcessProteinsPublic HealthReportingResearchResistanceResistance profileScreening procedureSeriesSiteStructural ModelsStructureStructure-Activity RelationshipSystemTechniquesTestingTherapeuticTherapeutic AgentsUnited States National Institutes of HealthUniversitiesValidationVariantViralViral Load resultVirusVirus DiseasesVirus ReplicationWorkX-Ray Crystallographyanalogbaseclinically relevantcomputing resourcesdaydesigndrug discoverydrug standardexperiencehigh throughput screeningimprovedinhibitor/antagonistmolecular modelingnext generationnovelpeptide Aprogramsprotein protein interactionresistance mechanismsimulationsmall moleculevirtual
项目摘要
DESCRIPTION (provided by applicant): The molecular mechanisms of resistance to viral entry fusion inhibitors targeting HIVgp41 are not well-understood. Fundamental gaps in knowledge of the energetic and structural interactions which drive binding hamper the long-term goal of development of new drugs with improved resistance profiles. The overall objective of this application is to (1) develop computational structural models to quantify binding for known gp41 fusion inhibitors (both peptides and small molecules), (2) characterize origins of resistance profiles to current inhibitors, and (3) discover new small molecule drug-leads. Based on strong preliminary results, the central hypothesis is that specific interactions within a conserved hydrophobic pocket on gp41, not exploited by the only currently available anti-fusion drug (peptide inhibitor T20), confer improved resistance profiles to next-generation peptide inhibitors and drive binding for small molecule inhibitors. The rationale for the proposed research is that robust computational models allow drug binding to be fully characterized at the atomic level, and this will enable development of HIV drugs with favorable resistance profiles. Thus, the work proposed is directly relevant to the NIH plan for basic and applied research towards discovery and development of novel agents and therapeutic strategies directed against viral factors involved in HIV replication and persistence. The work employs all-atom computer simulations (molecular dynamics and docking), in conjunction with detailed energetic and structural analysis, to test the central hypothesis and accomplish the goals set forth in each specific aim. Aim #1 will determine the molecular basis of resistance to current peptide fusion inhibitors of gp41 to test the hypothesis that binding affinity for T20 is driven primarily by interactions with mutation-prone regions along the binding interface. Aim #2 will characterize the mechanism of action for reported small molecule inhibitors of gp41 which we postulate are due to specific energetic and structural interactions modulated within the conserved pocket. Aim #3 will identify new small organic molecules, which bind specifically to the gp41 pocket, using virtual-high-throughput-screening in conjunction with experimental validation. Active compounds will be characterized structurally using NMR and X-ray crystallography and developed further. The proposal's contributions are significant because results from detailed binding models and computer simulations will allow the molecular basis of recognition to be delineated, which will enable development of improved fusion inhibitors that maintain activity against clinically relevant HIV escape mutations.
PUBLIC HEALTH RELEVANCE: Results from the proposed research will be used to uncover the atomic-level structural and energetic determinates which describe binding of membrane fusion inhibitors with the viral entry protein gp41 which mediates HIV infection. The proposal seeks to understand the origins of resistance to gp41 inhibitors, and develop new compounds with improved resistance profiles, thus the finding are expected to be of direct relevance to public health.
描述(由申请人提供):对靶向HIVgp41的病毒进入融合抑制剂耐药的分子机制尚不清楚。在驱动结合的能量和结构相互作用的知识方面的根本差距阻碍了开发具有改善的耐药性谱的新药的长期目标。本申请的总体目标是(1)开发计算结构模型以定量已知gp41融合抑制剂(肽和小分子)的结合,(2)表征对当前抑制剂的耐药谱的起源,以及(3)发现新的小分子药物先导。基于强有力的初步结果,中心假设是gp41上保守的疏水口袋内的特异性相互作用,目前唯一可用的抗融合药物(肽抑制剂T20)没有利用,赋予下一代肽抑制剂改善的耐药性,并驱动小分子抑制剂的结合。拟议研究的基本原理是,强大的计算模型允许在原子水平上充分表征药物结合,这将使开发具有良好耐药性的HIV药物成为可能。因此,建议的工作是直接相关的国家卫生研究院计划的基础和应用研究,以发现和开发新的代理商和治疗策略,直接针对病毒的因素参与艾滋病毒的复制和持久性。这项工作采用全原子计算机模拟(分子动力学和对接),结合详细的能量和结构分析,以测试中心假设并实现每个具体目标中提出的目标。目的#1将确定对gp41的当前肽融合抑制剂的抗性的分子基础,以检验对T20的结合亲和力主要由与沿着结合界面的突变倾向区域沿着的相互作用驱动的假设。目的#2将表征所报道的gp41小分子抑制剂的作用机制,我们假设这是由于保守口袋内调节的特定能量和结构相互作用。目标#3将使用虚拟高通量筛选结合实验验证来识别新的有机小分子,其特异性地结合到gp41口袋。活性化合物将使用NMR和X射线晶体学进行结构表征并进一步开发。该提案的贡献是重要的,因为详细的结合模型和计算机模拟的结果将允许识别的分子基础被描绘,这将使改进的融合抑制剂的开发,保持对临床相关的HIV逃逸突变的活性。
公共卫生相关性:拟议研究的结果将用于揭示原子水平的结构和能量决定因素,这些决定因素描述了膜融合抑制剂与介导HIV感染的病毒进入蛋白gp41的结合。该提案旨在了解对gp41抑制剂耐药性的起源,并开发具有改善耐药性的新化合物,因此该发现预计将与公共卫生直接相关。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT C. RIZZO其他文献
ROBERT C. RIZZO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT C. RIZZO', 18)}}的其他基金
Development, Validation, and Application of Structure-based Tools for Computational Molecular Design
基于结构的计算分子设计工具的开发、验证和应用
- 批准号:
10455100 - 财政年份:2018
- 资助金额:
$ 27.42万 - 项目类别:
Development, Validation, and Application of Structure-based Tools for Computational Molecular Design
基于结构的计算分子设计工具的开发、验证和应用
- 批准号:
10226099 - 财政年份:2018
- 资助金额:
$ 27.42万 - 项目类别:
A combined computational and experimental approach to the evolution and role of the DNA sequence environment in targeting mutations to antibody V regions
一种结合计算和实验的方法来研究 DNA 序列环境的进化和在抗体 V 区靶向突变中的作用
- 批准号:
10375356 - 财政年份:2018
- 资助金额:
$ 27.42万 - 项目类别:
Computational Design of Fusion Inhibitors Targeting Drug-resistant HIVgp41
针对耐药 HIVgp41 的融合抑制剂的计算设计
- 批准号:
8247014 - 财政年份:2008
- 资助金额:
$ 27.42万 - 项目类别:
Computational Design of Fusion Inhibitors Targeting Drug-resistant HIVgp41
针对耐药 HIVgp41 的融合抑制剂的计算设计
- 批准号:
8055893 - 财政年份:2008
- 资助金额:
$ 27.42万 - 项目类别:
Computational Design of Fusion Inhibitors Targeting Drug-resistant HIVgp41
针对耐药 HIVgp41 的融合抑制剂的计算设计
- 批准号:
7597119 - 财政年份:2008
- 资助金额:
$ 27.42万 - 项目类别:
Computational Design of Fusion Inhibitors Targeting Drug-resistant HIVgp41
针对耐药 HIVgp41 的融合抑制剂的计算设计
- 批准号:
8467315 - 财政年份:2008
- 资助金额:
$ 27.42万 - 项目类别:
Computational Design of Fusion Inhibitors Targeting Drug-resistant HIVgp41
针对耐药 HIVgp41 的融合抑制剂的计算设计
- 批准号:
7797534 - 财政年份:2008
- 资助金额:
$ 27.42万 - 项目类别:
Computational Design of Fusion Inhibitors Targeting Drug-resistant HIVgp41
针对耐药 HIVgp41 的融合抑制剂的计算设计
- 批准号:
8720786 - 财政年份:2008
- 资助金额:
$ 27.42万 - 项目类别:
Computational Design of Fusion Inhibitors Targeting Drug-resistant HIVgp41
针对耐药 HIVgp41 的融合抑制剂的计算设计
- 批准号:
8915303 - 财政年份:2008
- 资助金额:
$ 27.42万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 27.42万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 27.42万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 27.42万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 27.42万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 27.42万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 27.42万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 27.42万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 27.42万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 27.42万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 27.42万 - 项目类别:
Grant-in-Aid for Early-Career Scientists